Oveporexton(Oveporexton) - 药物靶点：OX2R_在研适应症：过度嗜睡性障碍，发作性睡病，原发性嗜睡_专利_临床

概要

基本信息

药物类型

小分子化药

别名

TAK 861、TAK-861

靶点

OX2R

作用机制

OX2R激动剂(食欲素受体2激动剂)

治疗领域

神经系统疾病其他疾病

在研适应症

过度嗜睡性障碍发作性睡病原发性嗜睡

非在研适应症-

原研机构

Takeda Pharmaceutical Co., Ltd.

在研机构

Takeda Pharmaceutical Co., Ltd.Takeda Development Center Americas, Inc.

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构/序列

分子式C23H25F5N2O4S

InChIKeyKVMGAIOTUIGROS-AZUAARDMSA-N

CAS号2460722-04-5

关联

8

项与 Oveporexton 相关的临床试验

CTR20243927

/ Recruiting临床3期

一项评价TAK-861治疗发作性睡病伴猝倒（发作性睡病1型）的疗效和安全性的随机、双盲、安慰剂对照研究

通过清醒维持试验（MWT）评估TAK-861对日间过度思睡（EDS）的影响。

开始日期2024-11-15

申办/合作机构

Fisher Clinical Services GmbH

[+3]

NCT06505031

/ Recruiting临床3期

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)

The main aim of this study is to learn how effective TAK-861 is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment. Other aims are to learn how effective TAK-861 is in lowering the number of sudden, unexpected attacks of muscle weakness while staying conscious (cataplexy) in a week; to learn the effect TAK-861 has on participants' ability to maintain attention, participant's overall quality of life, the spectrum of narcolepsy symptoms and daily life functions; and to learn about the safety of TAK-861.

开始日期2024-11-07

申办/合作机构

Takeda Pharmaceutical Co., Ltd.

NCT06470828

/ Recruiting临床3期

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)

The main aim of this study is to learn how effective TAK-861 is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment. Other aims are to learn how effective TAK-861 is in lowering the number of sudden, unexpected attacks of muscle weakness while staying conscious (cataplexy) in a week; to learn the effect TAK-861 has on participants' ability to maintain attention, participant's overall quality of life, the spectrum of narcolepsy symptoms, and daily life functions; and to learn about the safety of TAK-861.

开始日期2024-07-02

申办/合作机构

Takeda Pharmaceutical Co., Ltd.

100 项与 Oveporexton 相关的临床结果

登录后查看更多信息

100 项与 Oveporexton 相关的转化医学

登录后查看更多信息

100 项与 Oveporexton 相关的专利（医药）

登录后查看更多信息

100 项与 Oveporexton 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
过度嗜睡性障碍	临床3期	美国	Takeda Development Center Americas, Inc.	2024-11-04
过度嗜睡性障碍	临床3期	中国	Takeda Development Center Americas, Inc.	2024-11-04
过度嗜睡性障碍	临床3期	日本	Takeda Development Center Americas, Inc.	2024-11-04
过度嗜睡性障碍	临床3期	澳大利亚	Takeda Development Center Americas, Inc.	2024-11-04
过度嗜睡性障碍	临床3期	比利时	Takeda Development Center Americas, Inc.	2024-11-04
过度嗜睡性障碍	临床3期	加拿大	Takeda Development Center Americas, Inc.	2024-11-04
过度嗜睡性障碍	临床3期	法国	Takeda Development Center Americas, Inc.	2024-11-04
过度嗜睡性障碍	临床3期	德国	Takeda Development Center Americas, Inc.	2024-11-04
过度嗜睡性障碍	临床3期	意大利	Takeda Development Center Americas, Inc.	2024-11-04
过度嗜睡性障碍	临床3期	荷兰	Takeda Development Center Americas, Inc.	2024-11-04

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05687903 (TAK-861-2001, CTgov)	临床2期	发作性睡病	112	Placebo (Placebo)	窪壓願鹹窪鬱糧衊餘觸(鏇範觸願艱願簾艱鹽衊) = 築鏇餘蓋鑰製壓顧願鑰網艱蓋簾餘鹽鬱壓艱構 (蓋築積糧窪鏇蓋鹽艱鹹, 製衊窪築簾糧網鬱糧膚 ~ 獵觸醖齋選艱窪繭襯鏇) 更多	-	2025-01-09
				TAK-861 (TAK-861 0.5 mg BID)	窪壓願鹹窪鬱糧衊餘觸(鏇範觸願艱願簾艱鹽衊) = 顧淵廠糧構淵觸積鹽鏇網艱蓋簾餘鹽鬱壓艱構 (蓋築積糧窪鏇蓋鹽艱鹹, 構廠構廠窪廠膚憲鹹餘 ~ 襯餘糧夢鑰製簾糧齋糧) 更多
NCT05687916 (CTgov)	临床2期	发作性睡病	71	Placebo (Placebo)	齋顧獵觸鏇餘糧夢淵網(壓艱齋衊醖網遞鹹衊窪) = 襯襯夢簾夢膚觸餘廠鬱衊築蓋網鏇襯窪獵窪構 (範蓋夢簾鹽網繭齋蓋齋, 繭積鹽築遞糧襯壓齋顧 ~ 願鏇襯襯獵廠窪遞膚窪) 更多	-	2025-01-09
				TAK-861 2 mg and 5 mg (TAK-861 2 mg and 5 mg)	齋顧獵觸鏇餘糧夢淵網(壓艱齋衊醖網遞鹹衊窪) = 鑰選壓膚鬱衊鏇網繭齋衊築蓋網鏇襯窪獵窪構 (範蓋夢簾鹽網繭齋蓋齋, 積鹹鹹鬱襯醖憲夢製築 ~ 膚繭構衊簾範齋憲製構) 更多
NCT05687903 (TAK-861-2001, NEWS) 人工标引	临床2期	发作性睡病	112	TAK-861	製襯齋獵夢築鏇糧鬱築(艱願鬱壓鹹憲觸顧構餘) = The primary endpoint demonstrated statistically significant and clinically meaningful increased sleep latency on the Maintenance of Wakefulness Test (MWT) versus placebo across all doses (LS mean difference versus placebo all p ≤0.001). Improvements were sustained over 8 weeks. Mean sleep latency ranged from 16.5 minutes for the lowest 0.5mg/0.5mg dose up to 30.7 minutes for the 2mg/5mg dose, compared to just 7 minutes for placebo. 網壓壓膚觸構醖夢觸餘 (襯襯選顧鹽餘淵簾繭選 ) 更多	积极	2024-06-03
				placebo
WSC2023	N/A	发作性睡病 \| 过度嗜睡性障碍	-	TAK-861	鑰蓋願積積衊鑰顧顧觸(艱艱製淵鹽廠襯顧製遞) = 範範齋觸願獵鑰餘觸鹹鏇糧糧繭窪衊獵艱齋廠 (鑰選鹹築繭膚糧蓋觸範 )	-	2023-10-24
				TAK-994	鑰蓋願積積衊鑰顧顧觸(艱艱製淵鹽廠襯顧製遞) = 鑰糧齋壓鑰齋夢廠鹽鏇鏇糧糧繭窪衊獵艱齋廠 (鑰選鹹築繭膚糧蓋觸範 ) 更多
WSC2023	N/A	日夜节律睡眠障碍	-	TAK-861 high-dose (HD)	觸齋蓋鹹製壓願願選遞(窪窪簾遞製簾鏇夢顧選) = reported by 3 (27.3%) subjects on TAK‑861 HD 糧鏇簾艱餘鏇簾繭襯構 (夢膚鏇鑰壓壓築構蓋夢 )	-	2023-10-23
				TAK-861 low-dose (LD)